NegotiumBio supports pharmaceutical and biotech companies in executing outsourced manufacturing and procurement strategies across diverse modalities. Our successful negotiation track record includes small and large molecules as well as cell & gene therapies, including CAR-T, TCR, viral vector, plasmid, mAB, protein, and CRISPR based therapies. Whatever modality your drug may be, we’ve got you covered in terms of identifying and mitigating outsourcing risks and maximizing cost effectiveness – helping you make the deal that best leverages your resources.